ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Pegcetacoplan Long Term Safety and Efficacy Extension Study

ClinicalTrials.gov ID: NCT03531255

Public ClinicalTrials.gov record NCT03531255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study identification

NCT ID
NCT03531255
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Enrollment
160 participants

Conditions and interventions

Conditions

Interventions

  • Pegcetacoplan Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 26, 2018
Primary completion
Nov 28, 2025
Completion
Jun 30, 2026
Last update posted
Apr 5, 2026

2018 – 2026

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
University of Southern California Los Angeles California 90033
Denver Health Medical Center Denver Colorado 80204
Cancer Specialists of North Florida Jacksonville Florida 32257
Lakes Research Miami Florida 33014
Northwestern University Chicago Illinois 60611
Investigative Clinical Research of Indiana Indianapolis Indiana 46260
Duke University Medical Center Durham North Carolina 27710
Cleveland Clinic Cleveland Ohio 44195
Baptist Cancer Center Memphis Tennessee 38120

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03531255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 5, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03531255 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →